Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony Biosciences announced that six abstracts regarding narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026. The presentations cover pooled analyses of pitolisant, Phase 3 data for HBS-301, and a Phase 1b dosing study for the gastro-resistant formulation HBS-201.
Key figures
- Drug Name
- Pitolisant, HBS-301, HBS-201
- Abstract count
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.